	US 12,202,884 B2
	Nucleic acids encoding switch receptors using IL-9 receptor signaling domains
John Connolly, Red Oak, TX (US); and Sean Parker, San Francisco, CA (US)
Assigned to Parker Institute for Cancer Immunotherapy, San Francisco, CA (US)
Filed by Parker Institute for Cancer Immunotherapy, San Francisco, CA (US)
Filed on Sep. 16, 2022, as Appl. No. 17/946,916.
Claims priority of provisional application 63/245,661, filed on Sep. 17, 2021.
Prior Publication US 2023/0265163 A1, Aug. 24, 2023
Int. Cl. C07K 14/705 (2006.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01); C07K 14/71 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01)

CPC C07K 14/7155 (2013.01) [C07K 14/70578 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464406 (2023.05); A61K 39/464419 (2023.05); A61K 39/464474 (2023.05); A61K 2239/23 (2023.05); A61K 2239/53 (2023.05); A61K 2239/59 (2023.05); C07K 14/70503 (2013.01); C07K 14/70521 (2013.01); C07K 14/71 (2013.01); C07K 2319/03 (2013.01); C07K 2319/32 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01)]

29 Claims

1. A recombinant nucleic acid molecule encoding a chimeric receptor, said chimeric receptor comprising:

an extracellular portion comprising a binding domain of an endogenous inhibitory receptor, wherein the endogenous inhibitory receptor comprises the amino acid sequence of SEQ ID NO: 10;

an intracellular portion comprising the endodomain of IL-9 receptor alpha linked to a BOX1/2 common gamma chain domain, wherein the endodomain of IL-9 receptor alpha comprises the amino acid sequence of SEQ ID NO: 57 and the BOX1/2 common gamma chain domain comprises SEQ ID NO: 58; and

a transmembrane domain that joins the extracellular portion and the intracellular portion.